Widening Pharma Pessimism On China Amid Falling Profitability
This article was originally published in PharmAsia News
Despite the health care sector generally faring well in the general economic slowdown in China, pharma companies say they are becoming less profitable in this market, and are still concerned about IPR and regulatory reform issues, notes a new European Chamber of Commerce business confidence survey.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.